EOLSEvolus, Inc.
The Read
2% respectively, while industry pricing pressures led to a muted 2.
The schedule
- Thu1Oct
Regulatory update for Evolysse™ Sculpt in the US, with potential implications for product launch and market expansion.
- Tue20Oct
Potential equity or convertible offering to raise capital for R&D and expansion.
- Wed4Nov
Earnings report for Q3 2026, with focus on revenue growth and guidance for 2027.
- Wed20Jan
Revenue guidance and long-term outlook for 2027, with focus on growth and innovation.
- Sun14Feb
Earnings report for Q4 2026, with focus on revenue growth and guidance for 2027.
- Mon10May
Earnings report for Q1 2027, with focus on revenue growth and guidance for 2028.
- Wed4Aug
Earnings report for Q2 2027, with focus on revenue growth and guidance for 2028.
Past
- Thu10Sep
Market check for aesthetic products, assessing demand and competitive positioning.
- Wed5Aug
Actual outcome: Bull · $8.12 at outcome
Evolus reported strong Q2 2026 results featuring 21% revenue growth and its third consecutive quarter of positive adjusted EBITDA, alleviating concerns over discretionary spending headwinds. The stock rallied sharply as the company raised the lower end of its full-year revenue outlook, cited market-share gains across its aesthetic portfolio, and announced an expanded international partnership with Symatese.
Evolus reports Q2 2026 results with shares anchoring at $6.94. Focus will be on whether the recent pivot to positive Adjusted EBITDA is sustained amidst discretionary spending headwinds.
- Wed1Jul
Actual outcome: Bull · $6.85 at outcome
Evolus shares rallied past the bull target as strong underlying cash flow and sales performance alleviated concerns over the company's liquidity needs. By demonstrating sufficient capital to fund operations and product launches without immediately tapping the expensive Pharmakon debt facility, the company significantly reduced near-term financing risks and drove investor confidence.
Evaluation of liquidity needs and the potential tapping of the expensive Pharmakon debt facility to fund operations and product launches.
- Mon15Jun
Actual outcome: Bear · $6.59 at outcome
The stock saw a muted 2.4% decline during the target window as mid-year channel checks yielded ambiguous signals regarding the impact of competitor discounting. While AbbVie's aggressive promotional activities remained a persistent headwind, the lack of severe market share deterioration for EOLS kept the stock range-bound, leaving investors in a wait-and-see mode.
Mid-year channel checks assessing the impact of aggressive promotional activity and pricing strategies from dominant competitors like AbbVie.
- Mon4May
Actual outcome: Bull · $6.32 at outcome
Evolus reported Q1 2026 results that met EPS estimates and delivered a second consecutive quarter of positive Adjusted EBITDA, proving its recent profitability pivot was sustainable rather than a holiday anomaly. The company also reaffirmed its full-year outlook and announced the upcoming commercial launch of its Estyme injectable HA gels in Europe. This combination of sustained margin improvement and international expansion drove the stock up 13.3%, easily exceeding the bull target.
Q1 earnings will test if the Q4 EPS positivity was a holiday anomaly or a sustainable margin pivot.
- Tue3Mar
Actual outcome: Bull · $5.53 at outcome
Evolus matched Q4 earnings estimates and reported nearly $300 million in 2025 revenue, but the primary driver was management's official confirmation that the company expects to achieve sustainable annual profitability starting in 2026. This validation of the business model and the delivery of a sixth consecutive year of double-digit growth triggered a 33.9% rally as investors re-rated the stock based on the improved margin outlook.
Official confirmation of the positive Q4 2025 non-GAAP operating income and detailed path/assumptions for achieving sustainable annual profitability starting in 2026. This validates the business model and is key for re-rating.
